ADAURA2 is a global, phase III, randomized, double-blind, placebo-controlled trial designed to assess adjuvant osimertinib versus placebo in patients with stage IA2–IA3 EGFR-mutant NSCLC following curative-intent surgery. This evidence concerns the gene EGFR and non-small cell lung carcinoma.